Published in Am J Geriatr Psychiatry on March 01, 2011
Reconsideration of key articles regarding medication-related problems in older adults from 2011. Am J Geriatr Pharmacother (2012) 0.81
Common selective serotonin reuptake inhibitor side effects in older adults associated with genetic polymorphisms in the serotonin transporter and receptors: data from a randomized controlled trial. Am J Geriatr Psychiatry (2013) 0.77
Pharmacologic treatment of depression in the elderly. Can Fam Physician (2014) 0.75
Reduction of patient-reported antidepressant side effects, by type of collaborative care. Psychiatr Serv (2014) 0.75
Behavioral activation for depression in older adults: theoretical and practical considerations. Behav Anal (2013) 0.75
On-label and off-label use of high-dose influenza vaccine in the United States, 2010-2012. Hum Vaccin Immunother (2015) 0.75
Non-pharmacological treatment for depressed older patients in primary care: A systematic review and meta-analysis. PLoS One (2017) 0.75
Disparity in depression treatment among racial and ethnic minority populations in the United States. Psychiatr Serv (2008) 5.00
Prevalence of psychiatric disorders across Latino subgroups in the United States. Am J Public Health (2006) 4.15
Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm (2003) 3.34
Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes (2011) 3.25
Understanding differences in past year psychiatric disorders for Latinos living in the US. Soc Sci Med (2007) 2.49
Prevalence and correlates of eating disorders in Latinos in the United States. Int J Eat Disord (2007) 2.44
Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care (2003) 2.33
Costs of necrotizing enterocolitis and cost-effectiveness of exclusively human milk-based products in feeding extremely premature infants. Breastfeed Med (2011) 2.12
Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale. Int Clin Psychopharmacol (2008) 1.91
Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance. Depress Anxiety (2010) 1.72
Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clin Infect Dis (2004) 1.65
A randomized, double-blind, placebo-controlled study of ziprasidone monotherapy in bipolar disorder with co-occurring lifetime panic or generalized anxiety disorder. J Clin Psychiatry (2014) 1.46
Cost-effectiveness of primary implanted cardioverter defibrillator for sudden death prevention in congestive heart failure. Cardiovasc Drugs Ther (2004) 1.46
Where's the value in health care? Value Health (2006) 1.45
Health insurance coverage for vulnerable populations: contrasting Asian Americans and Latinos in the United States. Inquiry (2006) 1.45
Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II. Value Health (2009) 1.43
Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res (2014) 1.34
Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a consensus statement. J Clin Psychiatry (2010) 1.27
Economic impact of antidiabetic medications and glycemic control on managed care organizations: a review of the literature. J Manag Care Pharm (2006) 1.26
Does managed health care reduce health care disparities between minorities and Whites? J Health Econ (2006) 1.22
Rates and implications for hospitalization of patients ≥65 years of age with atrial fibrillation/flutter. Am J Cardiol (2011) 1.20
A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder. J Clin Psychopharmacol (2014) 1.16
Sheehan Suicidality Tracking Scale (Sheehan-STS): Preliminary Results from a Multicenter Clinical Trial in Generalized Anxiety Disorder. Psychiatry (Edgmont) (2009) 1.14
Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial. J Clin Psychiatry (2010) 1.13
Good research practices for measuring drug costs in cost-effectiveness analyses: an international perspective: the ISPOR Drug Cost Task Force report--Part VI. Value Health (2009) 1.11
Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United States. Clin Cardiol (2010) 1.11
Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. Neuropsychopharmacology (2005) 1.10
Cost-effectiveness analysis of pharmaceutical care in a medicare drug benefit program. Value Health (2003) 1.09
Evaluating the cost-effectiveness of statins. J Manag Care Pharm (2004) 1.08
Trends in dual-energy X-ray absorptiometry in the United States, 2000-2009. J Clin Densitom (2011) 1.07
Sheehan Suicidality Tracking Scale (S-STS): reliability, convergent and discriminative validity in young Italian adults. Compr Psychiatry (2013) 1.06
The economic burden of fibromyalgia: comparative analysis with rheumatoid arthritis. Curr Med Res Opin (2009) 1.06
Health care costs in US patients with and without a diagnosis of osteoarthritis. J Pain Res (2012) 1.05
Effect of influenza-like illness and other wintertime respiratory illnesses on worker productivity: The child and household influenza-illness and employee function (CHIEF) study. Vaccine (2010) 1.04
Prevalence and correlates of dual diagnoses in U.S. Latinos. Drug Alcohol Depend (2008) 1.04
Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus. Adv Ther (2014) 1.01
Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial. Eur Neuropsychopharmacol (2012) 0.99
Where do I send thee? Does physician-ownership affect referral patterns to ambulatory surgery centers? Health Aff (Millwood) (2008) 0.98
Neuronal nicotinic receptor inhibition for treating mood disorders: preliminary controlled evidence with mecamylamine. Depress Anxiety (2002) 0.98
Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a brief report. J Clin Psychiatry (2010) 0.98
Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV. Value Health (2009) 0.98
Good research practices for measuring drug costs in cost effectiveness analyses: an industry perspective: the ISPOR Drug Cost Task Force report--Part V. Value Health (2009) 0.96
Understanding the underlying drivers of inpatient cost growth: a literature review. Am J Manag Care (2003) 0.96
Good research practices for measuring drug costs in cost-effectiveness analyses: a managed care perspective: the ISPOR Drug Cost Task Force report--Part III. Value Health (2009) 0.96
Significance of endorsement of psychotic symptoms by US Latinos. J Nerv Ment Dis (2009) 0.96
The cost to managed care of managing pulmonary hypertension. J Med Econ (2012) 0.93
The role of active family nutritional support in Navajos' type 2 diabetes metabolic control. Diabetes Care (2003) 0.93
Cost of illness in patients with metastatic colorectal cancer. J Med Econ (2010) 0.93
Antidepressant use in a nationally representative sample of community-dwelling US Latinos with and without depressive and anxiety disorders. Depress Anxiety (2009) 0.91
Healthcare costs associated with osteoarthritis in US patients. Pain Pract (2012) 0.91
Onychomycosis: health-related quality of life considerations. Pharmacoeconomics (2002) 0.91
Effects of ambulatory-care pharmacist consultation on mortality and hospitalization. Am J Manag Care (2003) 0.91
Outpatient red blood cell transfusion payments among patients on chronic dialysis. BMC Nephrol (2012) 0.90
Potential health care cost savings associated with early treatment of multiple sclerosis using disease-modifying therapy. Clin Ther (2011) 0.90
Adherence and persistence with single-dosage form extended-release niacin/lovastatin compared with statins alone or in combination with extended-release niacin. Ann Pharmacother (2006) 0.89
Long term healthcare costs of infants who survived neonatal necrotizing enterocolitis: a retrospective longitudinal study among infants enrolled in Texas Medicaid. BMC Pediatr (2013) 0.88
The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States. Neuro Oncol (2013) 0.87
Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders. Expert Rev Neurother (2009) 0.87
Spectrum of carpal dislocations and fracture-dislocations: imaging and management. AJR Am J Roentgenol (2014) 0.86
Comparative effectiveness of statin plus fibrate combination therapy and statin monotherapy in patients with type 2 diabetes: use of propensity-score and instrumental variable methods to adjust for treatment-selection bias. Pharmacoepidemiol Drug Saf (2012) 0.85
Evaluation of the effect of duloxetine treatment on functioning as measured by the Sheehan disability scale: pooled analysis of data from six randomized, double-blind, placebo-controlled clinical studies. Int Clin Psychopharmacol (2012) 0.85
Insomnia-related comorbidities and economic costs among a commercially insured population in the United States. Curr Med Res Opin (2009) 0.85
Humanistic and economic burden of generalized anxiety disorder in North America and Europe. J Affect Disord (2011) 0.85
The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006. Curr Med Res Opin (2008) 0.85
Depression: underdiagnosed, undertreated, underappreciated. Manag Care (2004) 0.85
Costs and benefits of male circumcision. JAMA Pediatr (2013) 0.85
Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine. Neuropsychopharmacology (2008) 0.83
Burden of chronic sleep maintenance insomnia characterized by nighttime awakenings among anxiety and depression sufferers: results of a national survey. Prim Care Companion J Clin Psychiatry (2010) 0.83
Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. J Psychiatr Res (2002) 0.83
Asthma costs and utilization in a managed care organization. J Allergy Clin Immunol (2008) 0.83
The direct costs of untreated comorbid insomnia in a managed care population with major depressive disorder. Curr Med Res Opin (2010) 0.83
Establishing the real cost of depression. Manag Care (2002) 0.83
Effects of benefit design change across 5 disease states. Am J Manag Care (2007) 0.81
Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States. Eur Neuropsychopharmacol (2012) 0.81
An economic evaluation of therapeutic alteration in the management of insomnia. Curr Med Res Opin (2009) 0.81
Burden of chronic sleep maintenance insomnia characterized by nighttime awakenings. Popul Health Manag (2010) 0.81
Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States. Pharmacoeconomics (2013) 0.80
Comparison of second-generation antipsychotic treatment on psychiatric hospitalization in Medicaid beneficiaries with bipolar disorder. J Med Econ (2011) 0.80
Testing language effects in psychiatric epidemiology surveys with randomized experiments: results from the National Latino and Asian American Study. Am J Epidemiol (2008) 0.80
Zolpidem extended-release 12.5 mg associated with improvements in work performance in a 6-month randomized, placebo-controlled trial. Sleep (2008) 0.80
Appropriate econometric methods for pharmacoeconometric studies of retrospective claims data: an introductory guide. J Manag Care Pharm (2005) 0.79
Using global ratings of health plans to improve the quality of health care. J Health Econ (2008) 0.79
A review of the clinical and economic outcomes of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. Expert Opin Pharmacother (2007) 0.79
Attending work while sick: implication of flexible sick leave policies. J Occup Environ Med (2010) 0.79
Impact of nighttime awakenings on worker productivity and performance. J Occup Environ Med (2010) 0.79
Perceived stress in anxiety disorders and the general population: a study of the Sheehan stress vulnerability scale. Psychiatry Res (2007) 0.79
Real-world evaluation of health-care resource utilization and costs in employees with fibromyalgia treated with pregabalin or duloxetine. Pain Pract (2010) 0.79
Healthcare utilization among patients with depression before and after initiating duloxetine in the United Kingdom. J Med Econ (2012) 0.79
Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis. Expert Rev Pharmacoecon Outcomes Res (2015) 0.79
No Evidence of an Association Between Efavirenz Exposure and Suicidality Among HIV Patients Initiating Antiretroviral Therapy in a Retrospective Cohort Study of Real World Data. Medicine (Baltimore) (2016) 0.78
Cost-benefit analysis of in-hospital influenza vaccination of postpartum women. Obstet Gynecol (2012) 0.78
Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer. Cancer (2009) 0.78
The influence of co-morbidities on prescribing pharmacotherapy for insomnia: evidence from US national outpatient data 1995-2004. J Med Econ (2008) 0.78
Red blood cell (RBC) transfusion rates among US chronic dialysis patients during changes to Medicare end-stage renal disease (ESRD) reimbursement systems and erythropoiesis stimulating agent (ESA) labels. BMC Nephrol (2014) 0.78
Economic burden of Pseudomonas aeruginosa infection in patients with cystic fibrosis. J Med Econ (2011) 0.77
The use of research measures in adult clinical practice. Innov Clin Neurosci (2011) 0.77
Healthcare utilization and cost effects of prior authorization for pregabalin in commercial health plans. Am J Manag Care (2010) 0.77
Adequacy of pharmacotherapy among medicaid-enrolled patients newly diagnosed with obsessive-compulsive disorder. CNS Spectr (2009) 0.77
Efficacy of bypassing agents in patients with hemophilia and inhibitors: a systematic review and meta-analysis. Clin Ther (2012) 0.77
Prior authorization of newer insomnia medications in managed care: is it cost saving? J Clin Sleep Med (2007) 0.77